J&J makes new investments in microbiome R&D; UK’s Arix out to raise £100 million for new biotech investments

Dirk Gevers

• J&J is making some new investments in microbiome research, including adding Caelus Health to its J&J Innovation portfolio. “These collaborations and investments will create critical new insights to address metabolic disorders through microbiome-based diagnostics and therapeutics,” said Dirk Gevers, PhD, Global Head, Janssen Human Microbiome Institute. “By partnering with entrepreneurs, biotechs and academics and bringing innovative opportunities together with our expertise, we look to move microbiome science forward and deliver future solutions that promote individual health.”

• London-based Arix Bioscience is looking to raise £100 million to invest in new biotech companies. Arix is planning a listing for the raise, looking to sell shares at 200 pence each. The firm has close ties with a range of top research centers in the UK.

• Mustang Bio, a subsidiary of Fortress Biotech $FBIO, says it has raised $94.5 million in a private placement, with plans to spend the cash on CAR-T development work. Their initial work is on brain cancer and acute myeloid leukemia. Not much has been reported about this company.

Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy